Dr. Harald Hübner

Lehrstuhl für Pharmazeutische Chemie

Development of a bivalent dopamine D2 receptor agonist (2011) Kühhorn J, Götz A, Hübner H, Thompson D, Whistler J, Gmeiner P Journal article, Original article Dopamine D2-like receptor agonists induce penile erection in male rats: Differential role of D2, D3 and D4 receptors in the paraventricular nucleus of the hypothalamus (2011) Sanna F, Succu S, Hübner H, Gmeiner P, Argiolas A, Melis MR Journal article, Original article Bivalent dopamine D2 receptor ligands: Synthesis and binding properties (2011) Kühhorn J, Hübner H, Gmeiner P Journal article, Original article Recent advances in the search for D3- and D4- selective drugs: Probes, models and candidates (2011) Löber S, Hübner H, Tschammer N, Gmeiner P Journal article, Review article Discovery of highly potent and neurotensin receptor 2 selective neurotensin mimetics (2011) Einsiedel J, Held C, Hervet M, Plomer M, Tschammer N, Hübner H, Gmeiner P Journal article, Original article Highly potent 5-aminotetrahydropyrazolopyridines: Enantioselective dopamine D3 receptor binding, functional selectivity, and analysis of receptor-ligand interactions (2011) Tschammer N, Elsner J, Götz A, Ehrlich K, Schuster S, Ruberg M, Kühhorn J, et al. Journal article, Original article The bulky N(6) substituent of cabergoline is responsible for agonism of this drug at serotonin 5-HT2a and 5-HT2b receptors and thus a determinant of valvular heart disease (2011) Kekewska A, Hübner H, Gmeiner P, Pertz HH Journal article Radical arylation of tyrosine and its application in the synthesis of a highly selective neurotensin receptor 2 ligand (2011) Pratsch G, Unfried JF, Einsiedel J, Plomer M, Hübner H, Gmeiner P, Heinrich M Journal article, Original article On the terminal homologation of physiologically active peptides as a means of increasing stability in human serum - Neurotensin, opiorphin, B27-KK10 epitope, NPY (2011) Seebach D, Lukaszuk A, Patora-Komisarska K, Podwysocka D, Gardiner J, Ebert MO, Reubi JC, et al. Journal article, Original article The bulky N(6) substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine (5-HT)2A and 5-HT2B receptors and thus is a determinant of valvular heart disease (2011) Kekewska A, Hübner H, Gmeiner P, Pertz HH Journal article, Original article